Fri, Feb 27, 2015, 10:15 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

jpifer 5 posts  |  Last Activity: Feb 24, 2015 1:00 AM Member since: Oct 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jpifer Feb 24, 2015 1:00 AM Flag

    ...Cel-sci went through 4 different teams with the old CRO while enrollment kept plunging.....arbitration..may actually come to fruition....thx

    Sentiment: Strong Buy

  • ........... Now, here’s the remarkable and truly astonishing thing about Multikine: the company developing this science believes that it has created a 4th treatment modality—immunotherapy delivered at the site of the primary tumor. No other company but CEL-SCI is pursuing this novel approach, as all other cancer immunotherapy is directed at recurrent cancer in patients. This is the specific revolutionary thrust of the CEL-SCI research and treatment construct. CEL-SCI hopes to use its focused immunotherapy to increase the “cure rate” and to potentially eliminate, or at least drastically reduce, the untoward and dreadful treatment modalities currently in use as the standard of care.

    Slightly off-topic but relevant as a comparable treatment evolution, consider how HIV/AIDS just a few years ago was looked at as a disease with a 100% dire prognosis. A single drug, zidovudine, was discovered that seemed to help those afflicted. Then, after a massive input of research, a combination therapy (i.e. a “cocktail” of drugs) was advanced in an accelerated FDA category to treat the disease to the point where the HIV antibody doesn’t show in blood tests at all (as long as the drug combination is taken by the patient in a very disciplined regimen). Gilead Sciences (GILD) developed one of those HIV cocktails and the shares of the company went from $0.27 to now over $100, with a market-cap of now $150 billion and sales of over $24 billion a year. Such is the reward—or “golden ring”—at the successful end of treating a condition once considered “untreatable” whose afflicted were doomed.

    Similarly, the hepatitis C combination therapy is thought to cure 96% of those patients who did not already have cirrhosis or liver cancer. Key players are AbbVie (ABBV) NYSE – (market-cap of $90 billion with sales of over $19 billion) and Gilead Sciences (GILD), here again at the forefront. Hepatitis C is another terrible condition that now is treatable with a combination therapy.

    Sentiment: Strong Buy

  • Reply to

    ...what is seekingalpha talking about...

    by jpifer Feb 18, 2015 10:37 PM jpifer Feb 18, 2015 10:54 PM Flag was great..

  • ......A high-stakes trial that could increase the company's worth by more than 50% starts 3 months from now. Stay away til then. .....

    Sentiment: Strong Buy

  • ..arbitration goes well...the marketcap will have to correct itself...cheers

1.04+0.08(+8.79%)Feb 27 4:03 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.